Cost-effectiveness of telemedicine care for patients with uncontrolled type 2 diabetes mellitus during the COVID-19 pandemic in Saudi Arabia.
Cost-effectiveness of telemedicine care for patients with uncontrolled type 2 diabetes mellitus during the COVID-19 pandemic in Saudi Arabia.
复制标题
DOI：
10.1177/20406223211042542
复制
发表时间：
2021
影响因子：
3.5
通讯作者：
AlRuthia Y
中科院分区：
文献类型：
--
作者：
Faleh AlMutairi M;Tourkmani AM;Alrasheedy AA;ALHarbi TJ;Bin Rsheed AM;ALjehani M;AlRuthia Y
远程医疗可用于提供具有积极临床效果的糖尿病护理。因此，本研究评估了远程医疗对未控制的2型糖尿病患者（即HbA 1c>9）的成本效益。这是一项回顾性图表审查的患者不受控制的2型糖尿病参加门诊综合护理诊所。该研究包括两个组，即远程医疗护理模式和传统护理模式，每组100名患者。确定两组的临床有效性（即HbA 1c降低）和总成本，并计算增量成本-效果比。本研究采用倾向评分匹配法。远程医疗护理模式的患者HbA 1c水平平均降低1.82（95% CI = 1.56-2.09，p <0.001），而传统护理模式的患者平均降低1.54（95% CI = 1.23-1.85，p < 0.001）。 因此，增量效应为0.28（95% CI =-0.194至0.546）。在远程医疗和传统护理模式中，患者的平均总成本分别为4819.76 SAR（1285.27美元）和4150.69 SAR（1106.85美元）。因此，增量成本为669.07 SAR（178.42美元）[95% CI = 593.7 SAR（158.32美元）-1013.64 SAR（270.30美元）]。HbA 1c水平每降低1%，ICER估计为2372.52 SAR（632.67美元）。此外，远程医疗护理模式带来了更高的成本和更好的结果（即降低HbA 1c水平），置信度为81.80%。远程医疗护理在管理控制不佳的2型糖尿病患者方面具有成本效益。因此，我们认为，远程医疗护理可以进一步扩大，并纳入常规糖尿病护理。
Telemedicine could be used to provide diabetes care with positive clinical outcomes. Consequently, this study evaluated the cost-effectiveness of telemedicine for patients with uncontrolled type 2 diabetes mellitus (i.e. HbA1c >9). This was a retrospective chart review of patients with uncontrolled type 2 diabetes attending an outpatient integrated care clinic. The study consisted of two arms, namely a telemedicine care model and a traditional care model with 100 patients in each. The clinical effectiveness (i.e. reduction in HbA1c) and the total cost in both arms were determined, and the incremental cost-effectiveness ratio was calculated. This study adopted propensity score matching. The patients in the telemedicine care model had a mean reduction in their HbA1c level of 1.82 (95% CI = 1.56–2.09, p < 0.001), while those in the traditional care model had a mean reduction of 1.54 (95% CI = 1.23–1.85, p < 0.001). Consequently, the incremental effect was 0.28 (95% CI = −0.194 to 0.546). The mean total costs were SAR 4819.76 (US$1285.27) and SAR 4150.69 (US$1106.85) for patients in the telemedicine and traditional care models, respectively. Consequently, the incremental cost was SAR 669.07 (US$178.42) [95% CI = SAR 593.7 (US$158.32)–SAR 1013.64 (US$270.30)]. The ICER was estimated to be SAR 2372.52 (US$632.67) per 1% reduction in the level of HbA1c. Moreover, the telemedicine care model resulted in a higher cost and better outcome (i.e. reduction in the HbA1c level) with an 81.80% confidence level. Telemedicine care is cost-effective in managing type 2 patients with poorly controlled diabetes. Consequently, we believe that telemedicine care can be further expanded and incorporated into routine diabetes care.
登录
查看更多内容
影响因子：
5
作者：
Bode, Bruce;Garrett, Valerie;Klonoff, David C.
通讯作者：
Klonoff, David C.
影响因子：
3.7
作者：
Kenealy TW;Parsons MJ;Rouse AP;Doughty RN;Sheridan NF;Hindmarsh JK;Masson SC;Rea HH
通讯作者：
Rea HH
影响因子：
5
作者：
Al-Sofiani ME;Alyusuf EY;Alharthi S;Alguwaihes AM;Al-Khalifah R;Alfadda A
通讯作者：
Alfadda A
DOI：
10.3390/ijerph17010007
发表时间：
2020-01-01
影响因子：
--
作者：
Al Mansour, Mohammed Abdullah
通讯作者：
Al Mansour, Mohammed Abdullah
影响因子：
8.2
作者：
Corona G;Pizzocaro A;Vena W;Rastrelli G;Semeraro F;Isidori AM;Pivonello R;Salonia A;Sforza A;Maggi M
通讯作者：
Maggi M